Dr. Liu Mengzhong is a chief physician, professor and doctoral advisor. He graduated from the Department of Clinical Medicine at former Sun Yat-sen University of Medical Sciences (undergraduate program) in 1983 and was awarded a master's degree in Clinical Oncology by former Sun Yat-sen University of Medical Sciences in 1988. Currently he serves as Chief for Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Associate Chief for Oncology Teaching and Research Office of Sun Yat-sen University, and Chief for Radiation Oncology Teaching and Research Office of Sun Yat-sen University. He is also a member of the Chinese Society of Radiation Oncology of Chinese Medical Association, Chairman of Radiation Oncology Branch of Guangdong Medical Association, Chief for Guangdong Radiation Therapy Quality Control Center, and Deputy Chairman of Esophagus Cancer Specialized Committee of Guangdong Anti-cancer Association. Medical Specialties: rich clinical experience in combination therapy of radiation therapy and chemotherapy for thoracoabdominal tumors, nasopharynx carcinoma and prostate tumors.

In recent years, he has been mainly engaged in research of thoracoabdominal radiation therapy. He has carried out multi-centric clinical trial in esophagus cancer pre-operation chemoradiotherapy, which has made great progress. He has explored in concurrent chemoradiotherapy schemes and some of his papers in this field have been adopted by NCCN Guidelines. He has reached the leading level in China in thoracoabdominal advanced radiation therapy technologies (4D-CT\IGRT). He has undertaken several projects at national, provincial and ministerial levels. He has published about 70 papers as the lead author or corresponding author, over 20 of which have been included in SCI journals.

1. Xi M, Zhang L, Liu MZ (corresponding author), et al. Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLoS ONE. 2013; 8(5): e63864.2. Xi M, Zhang L, Liu MZ (corresponding author), et al. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162.3. Xi M, Liu SL, Liu MZ (corresponding author), et al. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013;8(12):e845864. Zhao L, He LR, Xi M, Liu MZ (corresponding author) et al. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3 . J Transl Med. 2012 Dec 11;10(1):249.5. Zhao L, Li QQ, Zhang R, Xi M, Liu MZ (corresponding author) et al. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour Biol. 2012 Aug;33(4):1115-23.6. Zhao L, He LR, Zhang R, Liu MZ (corresponding author) et al. Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2012 Dec;29(4):2669-76.7. Zhang L, Xi M, Deng XW, Liu MZ (corresponding author) et al. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012 Sep;53(5):769-76.8. Li Q, Hu Y, Xi M, Liu MZ (corresponding author) et al. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent mannerBMC Cancer. 2012 Oct 22;12:4859. Xi M, Zhang L, Liu MZ (corresponding author), Deng XW et al., Dosimertic Analysis of Respiratory-Gated Radiotherapy For Hepatocellular Carcinoma Medical Dosimetry. 2011;36(2):213-21810. Xi M, Liu MZ (corresponding author), Deng XW, et al. Radiation-Induced Sarcoma in Patients with Nasopharyngeal Carcinoma: A Single-Institution Study. Cancer. 2010; 116(23): 5479-5486. 11. He LR, Liu MZ (corresponding author), Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010; 127: 138-147.12. Xi M, Zhang L, Liu MZ (corresponding author), et al. Dosimetric Analysis of Respiratory Gated Radiotherapy for Hepatocellular Carcinoma. Med Dosim. 2010; in press. 13. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma. Dis Esophagus. 2010; 23: 253-259.14. Feng Z, Xu S, Liu MZ (all as lead authors), et al. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 2010; 297(2): 190-197.15. He LR, Liu MZ (corresponding author), Li BK, et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009 Dec 22; 9: 461. 16. He LR, Liu MZ (corresponding author), Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(9): 1591-1596.17. Xi M, Liu MZ (corresponding author), Zhang L, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259. 18. He LR, Liu MZ (corresponding author), Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(12): 2354-2360. 19. Chen Y, Liu MZ (both as lead authors), Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008; 71(5): 1356-1364. 20. Liu MZ, Tang LL, Zong JF, et al. Evaluation of Sixth Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement. Int J Radiat Oncol Biol Phys. 2008; 70(4): 1115-1123. 21. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008; 129(5): 728-734. 22. Xi M, Liu MZ (corresponding author), Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol, 2007, 84(3): 272-278.23. Xie CF, Liu MZ (corresponding author), Xi M. A comparative study on radiology and pathology target volume in hepatocellular carcinoma. Chinese Journal of Clinical Oncology. 2010; 37(21)24. Xi M, Liu MZ (corresponding author), Li .QQ, et al. Analysis of abdominal organ motion using four-dimensional CT. Chinese Journal of Cancer. 2009; 28(9): 989-993.25. Xi M, Liu MZ (corresponding author), Deng XW, et al. Definition of internal target volume and domestric study for hepatocellular carcinoma using four-dimensional CT. Chinese Journal of Radiation Oncology. 2009; 18(6): 435-439.26. Yang J, Liu MZ (corresponding author), Cai L, et al. Phase II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2008, 27(6): 622-62627. Xi M, Liu MZ (corresponding author), Deng XW, et al. Internal target volume definition using four-dimensional CT and dosimetric evaluation for hepatocellular carcinoma. Chinese Journal of Cancer, 2007, 26(1): 1-8.28. Liu MZ, He LR, Lu TX, et al. Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma. Chinese Journal of Oncology. 2006, 28(12): 932-937.29. Wang XS, Liu MZ (corresponding author), Zhang CQ, et al. Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients -- a report of 43 cases. Chinese Journal of Cancer, 2006, 25(11): 1428-1432.30. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Chinese Journal of Cancer, 2006, 25(6): 723-72731. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(6): 731-734.32. Cai L, Liu MZ (corresponding author), et al., Rong TH. Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2005, 24(5): 582-586.33. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(4): 498-501.34. Liu MZ, Wang XS, Cai L, et al. External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer. Chinese Journal of Cancer, 2005, 24(1): 82-86.Compilation of Books:1. Practical Radiation Oncology, Sun Yat-sen University Press, 1st edition, 12/2005 Associate Editor.2. Clinical Oncology, Science Press, 2nd edition, 09/2005 Editorial Board Member.3. Minimal Invasive Treatment and Multidisciplinary Compositive Treatment of Liver Cancer, Military Medical Science Press, 1st edition, 10/2003 Editorial Board Member.4. Radiation Therapy Handbook for Common Malignant Tumors, Peking University Medical Press, 1st edition, 01/2010 Chief Editor.Performance in projects at national, provincial and ministerial levels1. National Key Technologies R & D Program of China during the 9th Five-Year Plan Period: Clinical work of multidisciplinary compositive treatment for primary liver cancer (subtitle: clinical work of external radiation and combined TACE treatment for residual liver cancer). 01/1997 - 12/1999, RMB 50,000, completed.2. Science and Technology Program of Guangzhou, China (2001-Z-043-01-7): Clinical work of a new type of radiosensitizer (CM-Na) in treatment for nasopharynx carcinoma and primary liver cancer. 01/2002 - 12/2004, RMB 50,000, completed.3. Project of Guangdong Provincial Department of Science and Technology (2004B30301016): CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. 01/2005 - 12/2007, RMB 80,000, completed.4. Project of Guangdong Provincial Department of Science and Technology (2006B36002005): A study on 4D-CT respiratory gating radiation therapy for liver cancer. 01/2007 - 12/2009, RMB 50,000, completed.5. Project of Guangdong Provincial Department of Science and Technology (2009B080701036): A study on the clinical application of image guided radiation therapy to thoracoabdominal tumor. 01/2010 - 12/2012, RMB 150,000, completed.6. 2007 First person in charge of key specialties of Medicine in Guangdong (funded by Health Department of Guangdong Province, RMB 100,000 per year). 7. 2012 Clinical application of self-adaption radiation therapy (Project of Guangdong Provincial Department of Science and Technology 2012B031800287, RMB 100,000) 2013-2015 First person in charge.2012 A study on the influence of EGFR signal channel regulating IGFBP3 expression in esophagus cancer chemoradiotherapy sensibility and its mechanism (National Natural Science Foundation of China 81272487, RMB 700,000) 2013-2016 First person in charge

 

Last Updated on: July 2014.by International Office, Sun Yat-sen University Cancer Center